Pivotal Moment In EU For Potential New Drugs
Janssen’s Ponesimod Up For Approval Recommendation; Veklury Approval Due For Renewal
Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.
